Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Bicycle Therapeutics Ltd

BCYC
Current price
22.98 USD -0.12 USD (-0.52%)
Last closed 23.03 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 877 178 176 USD
Yield for 12 month -4.45 %
1Y
3Y
5Y
10Y
15Y
BCYC
21.11.2021 - 28.11.2021

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Address: Portway Building, Cambridge, United Kingdom, CB21 6GS

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

43.2 USD

P/E ratio

Dividend Yield

Current Year

+26 976 000 USD

Last Year

+14 463 000 USD

Current Quarter

+19 518 848 USD

Last Quarter

+5 331 000 USD

Current Year

+20 404 628 USD

Last Year

+10 776 277 USD

Current Quarter

+17 861 795 USD

Last Quarter

+3 662 612 USD

Key Figures BCYC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -173 212 000 USD
Operating Margin TTM -162.4 %
PE Ratio
Return On Assets TTM -23.04 %
PEG Ratio
Return On Equity TTM -56.13 %
Wall Street Target Price 43.2 USD
Revenue TTM 41 610 000 USD
Book Value 8.35 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 298.9 %
Dividend Yield
Gross Profit TTM -67 146 000 USD
Earnings per share -4.4 USD
Diluted Eps TTM -4.4 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BCYC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BCYC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BCYC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 13.4662
Price Sales TTM 31.3142
Enterprise Value EBITDA -2.1444
Price Book MRQ 2.2773

Financials BCYC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BCYC

For 52 weeks

12.54 USD 28.91 USD
50 Day MA 23.29 USD
Shares Short Prior Month 2 789 095
200 Day MA 20.17 USD
Short Ratio 6.95
Shares Short 2 885 352
Short Percent 8.06 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds


S

SX7EEX

14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics